AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+11.84%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.89B
AUM Growth
+$3.89B
(+0.38%)
Cap. Flow
-$658M
Cap. Flow
% of AUM
-16.88%
Top 10 Holdings %
Top 10 Hldgs %
78.03%
Holding
129
New
21
Increased
28
Reduced
28
Closed
19
Top Buys
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$96.7M |
| 2 |
Avidity Biosciences
RNA
|
$26.8M |
| 3 |
Cullinan Oncology
CGEM
|
$18.5M |
| 4 |
Merus
MRUS
|
$18.1M |
| 5 |
Vera Therapeutics
VERA
|
$14.8M |
Top Sells
| 1 |
CAVA Group
CAVA
|
$278M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$29.5M |
| 3 |
Viking Therapeutics
VKTX
|
$20.8M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$16.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$14.5M |
Sector Composition
| 1 | Consumer Discretionary | 56.42% |
| 2 | Healthcare | 42.2% |
| 3 | Technology | 0.99% |
| 4 | Financials | 0.15% |
| 5 | Consumer Staples | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Cullinan Oncology
CGEM
$456M
| $18.5M | 0.47% |
+1,057,949
| New | +$18.5M |
|
27
NewAmsterdam Pharma
NAMS
$2.8B
| $15.4M | 0.39% |
800,000
| – | – |
|
28
Xenon Pharmaceuticals
XENE
$2.99B
| $14.9M | 0.38% |
381,554
+128,167
| +51% | +$5M |
|
29
Edgewise Therapeutics
EWTX
$1.54B
| $14.6M | 0.37% |
811,718
| – | – |
|
30
Solid Biosciences
SLDB
$448M
| $14.2M | 0.36% |
2,500,000
| – | – |
|
31
Korro Bio
KRRO
$245M
| $14M | 0.36% |
413,072
-6,154
| -1% | -$208K |
|
32
Ascendis Pharma
ASND
$12.1B
| $13.8M | 0.35% |
+101,100
| New | +$13.8M |
|
|
AGEN
33
Agenus
AGEN
$136M
| $13M | 0.33% |
775,000
-14,856,235
| -95% | -$110K |
|
|
SYRS
34
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $12.9M | 0.33% |
2,505,013
| – | – |
|
35
Gossamer Bio
GOSS
$587M
| $12M | 0.31% |
13,308,968
| – | – |
|
36
Denali Therapeutics
DNLI
$2.24B
| $11.7M | 0.3% |
502,899
| – | – |
|
37
Ultragenyx Pharmaceutical
RARE
$3.04B
| $11.3M | 0.29% |
275,000
+97,068
| +55% | +$3.99M |
|
38
Biohaven
BHVN
$1.71B
| $10.6M | 0.27% |
+306,703
| New | +$10.6M |
|
39
Taysha Gene Therapies
TSHA
$791M
| $9.75M | 0.25% |
4,354,214
+666,666
| +18% | +$1.49M |
|
40
Lexeo Therapeutics
LXEO
$266M
| $9.68M | 0.25% |
603,435
-198,281
| -25% | -$3.18M |
|
|
SLRN
41
DELISTED
ACELYRIN
SLRN
| $8.91M | 0.23% |
2,020,888
-384,255
| -16% | -$1.69M |
|
42
Janux Therapeutics
JANX
$1.38B
| $8.5M | 0.22% |
203,000
+153,000
| +306% | +$6.41M |
|
43
Cartesian Therapeutics
RNAC
$267M
| $8.23M | 0.21% |
304,554
-8,832,081
| -97% | -$27 |
|
|
RAPP
44
Rapport Therapeutics
RAPP
$549M
| $8.14M | 0.21% |
+350,000
| New | +$8.14M |
|
45
Iovance Biotherapeutics
IOVA
$800M
| $8.11M | 0.21% |
+1,011,500
| New | +$8.11M |
|
46
Generation Bio
GBIO
$40.3M
| $7.98M | 0.2% |
2,830,591
| – | – |
|
47
Seer Inc
SEER
$114M
| $7.98M | 0.2% |
4,750,000
| – | – |
|
|
VIGL
48
DELISTED
Vigil Neuroscience
VIGL
| $7.31M | 0.19% |
1,828,691
+17,500
| +1% | +$70K |
|
49
MindMed
MNMD
$689M
| $7.27M | 0.19% |
+1,007,875
| New | +$7.27M |
|
50
Sea Limited
SE
$107B
| $6.96M | 0.18% |
97,500
-140,000
| -59% | -$10M |
|